Lynx Dx

Lynx Dx is a biotechnology and molecular diagnostics company headquartered in Ann Arbor, Michigan. Founded by clinical and research leaders connected with the University of Michigan, the company focuses on developing genomic tests that address important clinical needs.

Its flagship product, MyProstateScore 2.0 (MPS2), is a urine-based test that analyzes 18 gene transcripts to estimate the risk of clinically significant prostate cancer. The test is designed to provide physicians with additional information when evaluating patients and considering whether a prostate biopsy may be appropriate.

Lynx Dx works with healthcare providers and patients to make its diagnostic services accessible through in-office and at-home sample collection options.